| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8227230 | PFIZER | Human lysosomal proteins from plant cell culture |
Feb, 2024
(2 months ago) | |
| US8741620 | PFIZER | Human lysosomal proteins from plant cell culture |
Feb, 2024
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8790641 | PFIZER | Production of high mannose proteins in plant culture and therapeutic uses thereof |
Oct, 2025
(1 year, 5 months from now) | |
Elelyso is owned by Pfizer.
Elelyso contains Taliglucerase Alfa.
Elelyso has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Elelyso are:
- US8227230
- US8741620
Elelyso was authorised for market use on 01 May, 2012.
Elelyso is available in powder;intravenous dosage forms.
Elelyso can be used as a method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide..
Drug patent challenges can be filed against Elelyso from 01 May, 2016.
The generics of Elelyso are possible to be released after 18 October, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 27, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 01, 2017 |
Drugs and Companies using TALIGLUCERASE ALFA ingredient
NCE-1 date: 01 May, 2016
Market Authorisation Date: 01 May, 2012
Treatment: A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide.
Dosage: POWDER;INTRAVENOUS
ELELYSO family patents
List of large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8227230 | NA | NA |
Feb, 2024
(2 months ago) |